Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Prognostic Factors and Survival of Women with Breast Cancer Under 40 Years Old: A Single-Centre Experience
[PDF]           
Berrin Inanc, Ozlem Mermut

 

ABSTRACT

Objective: This retrospective research aimed to evaluate the results of treatment outcome and clinicopathological features of breast cancer patients under 40 years old.

Material and methods: A total of 80 patients who were receiving radiotherapy and/or chemotherapy treatment for breast cancer (<40 years old) were included in the study. 

Results: First-degree relatives with breast cancer history (p=0.028), oestrogen receptor positivity (p=0.012) and progesterone receptor positivity (p=0.017) were associated with overall survival. No prognostic factors were found in the multivariate Cox regression analysis for overall survival. In multivariate Cox regression analysis, we found breast-conserving surgery type (hazard ratio = 6.104. 95% confidence interval = 1.037–53.928, p=0.045), lymphovascular invasion presence (hazard ratio = 0.127, 95% confidence interval = 0.016–1.025, p=0.005) and curative radiotherapy doses (hazard ratio = 185.976, 95% confidence interval = 5.342–6474.1, p=0.004) as independent prognostic factors for disease-free survival. Overall, survival of 1, 3 and 5 years was 88%, 74% and 65%, respectively. Median was 48±2.6 (42.8–53.19) months. Also, 1-, 3- and 5-year disease-free survival was 85%, 67% and 27%, respectively. Median was 30±1.8 (27.4–32.5) months.

Conclusion: Breast cancer patients under the age of 40 years are highly heterogeneous and are a complex patient group. The prognosis is worse in these patients, and prognostic factors and pathological subtypes should be taken into consideration when making treatment decisions.

Key words: breast cancer, prognostic factors, younger patients

 

Corresponding author: Berrin Inanc, MD, Department of Radiation Oncology, S.B.U. Istanbul Education Research Hospital, Istanbul, TR–34098, Turkey. Tel.: 902124596692. E-mail: byalcin77@hotmail.com

 

 

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7-30. https://doi.org/10.3322/caac.21590

2. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is Breast Cancer the Same Disease in Asian and Western Countries? World J Surg. 2010; 34:2308–2324. https://doi.org/10.1007/s00268-010-0683-1

3. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27:1160–1167. https://doi.org/10.1200/JCO.2008.18.1370

4. Gnerlich J, Deshpande A, Jeffe D, Sweet A, White N, Margenthaler J. Elevated breast cancer mortality in young women (<40 yrs) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg. 2009; 208(3):341-7. https://doi.org/10.1016/j.jamcollsurg.2008.12.001

5. Rodrэґguez-Cuevas S, Macэґas CG, Franceschi D, Labastida S. Breast Carcinoma Presents a Decade Earlier in Mexican Women than in Women in the United States or European Countries. Cancer. 2001; 91:863–868. https://doi.org/10.1002/1097-0142(20010215)91:4<863::AID-CNCR1074>3.0.CO;2-Y

6. Chia KS, Du WB, Sankaranarayanan R, Sankila R, Wang H, Lee J, et al. Do younger female breast cancer patients have a poorer prognosis? Results from a population-based survival analysis. Int J Cancer. 2004; 108:761–765. https://doi.org/10.1002/ijrc.11632 

7. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996; 77:97–103. https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3

8. Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017; 165(1):193–200. https://doi.org/10.1007/s10549-017-4325-2

9. Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤ 40 years) early breast cancer patients: a systematic metaanalysis comparing breastconserving surgery versus mastectomy. Breast. 2015; 24:175–181. https://doi.org/10.1016/j.breast.2015.02.002

10. Laurberg T, Lyngholm CD, Christiansen P, Alsner J, Overgaard J. Longterm agedependent failure pattern after breastconserving therapy or mastectomy among Danish lymphnodenegative breast cancer patients. Radiother Oncol. 2016; 120:98–106. https://doi.org/10.1016/j.radonc.2016.05.006

11. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004; 240(2):306–312. https://doi.org/10.1097/01.sla.0000133355.48672.22

12. Fein DA, Fowble BL, Hanlon AL, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol. 1997; 65:34–39. https://doi.org/10.1002/(sici)1096-9098(199705)65:1%3C34::aid-jso7%3E3.0.co;2-p

13. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629

14. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007; 25(22):3259–65. https://doi.org/10.1200/jco.2007.11.4991

15. Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005; 23:5973–5982. https://doi.org/10.1200/JCO.2005.05.551

16. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378:771–784. https://doi.org/10.1016/S0140-6736(11)60993-8

17. Hernandez-Aya LF, Chavez-MacGregor M, Lei X, Meric-Bernstam F, Buchholz T, Hsu L, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011; 29:2628–2634. https://doi.org/10.1200/JCO.2010.32.1877

18. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363:1938–1948. https://doi.org/10.1056/NEJMra1001389

19. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007; 109:1721–1728. https://doi.org/10.1002/cncr.22618

Volume 3, Number 57 (2020)